Login to Your Account

Transgene Seeks Deal for HCV Vaccine in Shifting Landscape

By Cormac Sheridan
Staff Writer

Wednesday, April 25, 2012
Transgene SA hopes interim data from a Phase II trial of its therapeutic vaccine for treating hepatitis C virus (HCV) infection, TG4040, is sufficient to secure a deal for its further development.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription